Collaborations are an important element  in Citryll’s  strategy to bring CIT-013 to clinical Proof of Concept  and ultimately to patients. We explore the broader potential for clinical utility of mitigating dysregulated NET activity  with academic collaborators and industry partners. Citryll has a  proprietary toolbox to study NET biology and protein citrullination and their role in human pathologies. This toolbox enables us together with  our academic  and industry  partners  to study  the role of NETs in human disease on the one hand and the medical utility of CIT-013  on the other hand. 

We are keen to explore  opportunities to collaborate and partner with companies whose expertise in relevant therapeutic areas and clinical development of therapeutic antibodies will aid  us in the development  of innovative medicines addressing true medical need. 

Part of Citryll’s strategy is to collaborate with academic groups with a keen interest and/or track-record in NET biology and translational research  and with proven  experience  in human explant and animal  in vivo  models for RA, SLE, Interstitial Lung Disease (ILD) and IPF, Asthma, vasculitis, cancer and Alzheimer’s disease.